Summary: Health Canada’s new Canadian Clinical Trial Search Portal makes it easier to find clinical trials authorized in Canada by condition, treatment, location, recruitment status and more. For people living with rare metabolic disorders and their families, it provides a simpler way to discover research opportunities taking place closer to home.

Summary: Repinatrabit, also known as JNT-517, is an investigational oral treatment being studied for PKU through a global Phase 3 program. As of September 2026, the Phase 3 study is recruiting adults with PKU, including at the M.A.G.I.C. Clinic in Calgary.

Summary: The PALomino study is collecting real-world information about pregnancy, breastfeeding and infant outcomes following exposure to Palynziq (pegvaliase) in people with PKU. Earlier case reports and small retrospective studies have provided encouraging information, but the evidence remains limited, making ongoing systematic pregnancy research especially important.

Summary: The APHENITY clinical program helped establish the evidence for sepiapterin, an oral treatment for PKU now approved in Canada as Sephience. Phase 3 and long-term extension research showed meaningful reductions in blood phenylalanine and, for many participants, increased dietary phenylalanine tolerance.

Summary: RareKids-CAN is inviting youth with rare diseases and caregivers to share how they search for and use medication-related information. The study aims to identify gaps in current resources and help shape clearer, more useful pharmacology education for rare-disease families across Canada.

Summary: A rare diagnosis is important information, but it is not the whole story. Use CanChild’s F-Words for Child Development to introduce your child’s strengths, relationships, interests and hopes to their school team.

Summary: Un diagnostic rare est une information importante, mais il ne raconte pas toute l'histoire. Utilisez les « Mes mots préférés » de CanChild pour présenter à l'équipe scolaire les forces, les relations, les intérêts et les aspirations de votre enfant.

Summary: According to the Agios announcement, the company has dosed the first participant in its Phase 1b clinical trial of AG-181 in adults with PKU.

Summary: Sepiapterin, Sephience, PKU, Phenylketonuria, Hyperphenylalaninemia, PKU treatment, PKU therapy, Phenylalanine-restricted nutritional therapy, Drug reimbursement, Rare disease treatment

Summary: sépiaptérine, Sephience, phénylcétonurie, PCU, hyperphénylalaninémie, traitement de la PCU, thérapie pour la PCU, thérapie nutritionnelle pauvre en phénylalanine, accès aux traitements, remboursement des médicaments, Agence des médicaments du Canada,

Summary: This article is presented in English. The article comes from Aurora Therapeutics. Cet article est presente en anglais. L'article provient d'Aurora Therapeutics.

Summary: Note en francais : Cet article est presente en francais. L'article provient de phenylcetonurie.ca. Auteur : Tristan Audet. English note: This article is presented in French. The article comes from phenylcetonurie.ca. Author: Tristan Audet.

Summary: This article is presented in English. The article comes from phenylcetonurie.ca. Author: Tristan Audet. Cet article est presente en anglais. L'article provient de www.phenylcetonurie.ca.

Summary: Cet article est presente en francais. L'article provient de Carnet Phénylcétonurie par Tristan. This article is presented in French. The article comes from Carnet Phénylcétonurie by Tristan.